FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Sci / Efficacy of Platelet-Rich Plasma in the Treatment of Equine ...
Veterinary sciences2025; 12(4); doi: 10.3390/vetsci12040382

Efficacy of Platelet-Rich Plasma in the Treatment of Equine Tendon and Ligament Injuries: A Systematic Review of Clinical and Experimental Studies.

Abstract: (1) Background: Tendon and ligament injuries are a leading cause of lameness in horses, with significant economic implications. Platelet-rich plasma (PRP) has gained attention for its regenerative potential, but its efficacy remains uncertain due to inconsistent study designs and reporting. (2) Methods: This systematic review, following the PRISMA guidelines, evaluated 22 studies (clinical and experimental) to assess the safety and efficacy of PRP in treating equine tendon and ligament injuries. The risk of bias was analyzed using the ROBINS-I and RoB 2.0 tools. (3) Results: PRP demonstrated a favorable safety profile, with no severe adverse effects reported. Clinical outcomes included improved lameness scores, ultrasonographic tissue organization, and return-to-work rates. However, variability in PRP formulations (e.g., leukocyte-rich vs. leukocyte-reduced) and activation methods (e.g., calcium chloride, thrombin) contributed to inconsistent results. Experimental studies supported PRP's role in collagen synthesis and neovascularization, but comparative trials with stem cells or other therapies (e.g., extracorporeal shockwave) showed mixed results. The methodological quality of studies varied, with only 27% achieving "good" scores for PRP reporting. (4) Conclusions: PRP is a safe and potentially effective treatment, but its clinical application is hindered by a lack of standardization. Future research should focus on large, randomized controlled trials with uniform PRP protocols, long-term (≥2 years) efficacy assessments, comparative studies with MSC combinations, and cost-effectiveness analyses.
Get Full Text
Publication Date: 2025-04-18 PubMed ID: 40284884PubMed Central: PMC12031177DOI: 10.3390/vetsci12040382Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research is a systematic review of 22 studies analyzing the effectiveness and safety of Platelet-Rich Plasma (PRP) in treating tendon and ligament injuries in horses. The review finds that PRP has a good safety profile and shows potential for effectively treating such injuries, but also notes variability in outcomes due to inconsistencies in study designs and PRP formulation methods.

Research Background

  • Tendon and ligament injuries are a major cause of lameness in horses and thus carry significant economic impact, making effective treatment methods crucial.
  • Platelet-rich plasma (PRP) has gained attention due to its potential for regenerative properties, but its efficacy remains uncertain due to inconsistent study designs and reporting methods.

Research Methods

  • The researchers followed PRISMA guidelines conducting this systematic review. They covered 22 studies, including both clinical and experimental works, to evaluate the safety and efficacy of PRP in treating equine tendon and ligament injuries.
  • The researchers examined the risk of bias in the studies analyzed using the ROBINS-I and RoB 2.0 tools.

Results of the Study

  • PRP demonstrated a positive safety profile, with no severe side effects reported in any of the studies reviewed.
  • Clinical outcomes from the studies showed positive results like improved lameness scores, better tissue organization when viewed through ultrasonography, and higher return-to-work rates.
  • However, inconsistent results were observed based on the variability in PRP formulations, such as leukocyte-rich versus leukocyte-reduced, and different activation methods (specifically calcium chloride and thrombin).
  • Experimental studies backed up PRP’s role in collagen synthesis and neovascularization, but trials comparing PRP with therapies like stem cells or extracorporeal shockwave offered mixed results.
  • The methodological quality of the studies reviewed varied significantly. Only about a quarter (27%) achieved “good” scores for their reporting on PRP.

Conclusions

  • The research concludes that PRP is a potentially effective and safe treatment for equine tendon and ligament injuries.
  • However, clinical application of PRP is hindered by lack of standardization in its use and reporting.
  • The researchers recommend future research to focus on randomized controlled trials with standardized PRP protocols, long-term efficacy assessments (2 years or more), comparative studies with bone marrow-derived mesenchymal stem cells, and cost-effectiveness analysis.

Cite This Article

APA
Carmona JU, López C. (2025). Efficacy of Platelet-Rich Plasma in the Treatment of Equine Tendon and Ligament Injuries: A Systematic Review of Clinical and Experimental Studies. Vet Sci, 12(4). https://doi.org/10.3390/vetsci12040382

Publication

Veterinary sciences
ISSN: 2306-7381
NlmUniqueID: 101680127
Country: Switzerland
Language: English
Volume: 12
Issue: 4

Researcher Affiliations

Carmona, Jorge U
  • Grupo de Investigación Terapia Regenerativa, Departamento de Salud Animal, Universidad de Caldas, Calle 65 No 26-10, Manizales 170004, Colombia.
López, Catalina
  • Grupo de Investigación Patología Clínica Veterinaria, Departamento de Salud Animal, Universidad de Caldas, Calle 65 No 26-10, Manizales 170004, Colombia.

Conflict of Interest Statement

The authors declare no conflicts of interest.

References

This article includes 67 references
  1. Dakin S.G., Dudhia J., Smith R.K.. Resolving an inflammatory concept: The importance of inflammation and resolution in tendinopathy.. Veter-Immunol. Immunopathol. 2014;158:121–127.
    doi: 10.1016/j.vetimm.2014.01.007pmc: PMC3991845pubmed: 24556326google scholar: lookup
  2. Dakin S.G., Dudhia J., Smith R.K.W.. Science in brief: Resolving tendon inflammation. A new perspective.. Equine Veter. J. 2013;45:398–400.
    doi: 10.1111/evj.12030pubmed: 23738877google scholar: lookup
  3. Smith R.K.W., McIlwraith C.W.. “One Health” in tendinopathy research: Current concepts.. J. Orthop. Res. 2021;39:1596–1602.
    doi: 10.1002/jor.25035pubmed: 33713481google scholar: lookup
  4. Clegg P.D.. Musculoskeletal disease and injury, now and in the future. Part 2: Tendon and ligament injuries.. Equine Veter. J. 2012;44:371–375.
    doi: 10.1111/j.2042-3306.2012.00563.xpubmed: 22486548google scholar: lookup
  5. Kasashima Y., Takahashi T., Smith R.K.W., Goodship A.E., Kuwano A., Ueno T., Hirano S.. Prevalence of superficial digital flexor tendonitis and suspensory desmitis in Japanese Thoroughbred flat racehorses in 1999.. Equine Veter. J. 2004;36:346–350.
    doi: 10.2746/0425164044890580pubmed: 15163043google scholar: lookup
  6. USDA. National Economic Cost of Equine Lameness, Colic, and Equine Protozoal Myeloencephalitis in the United States.. USDA APHIS Centers of Epidemiology and Animal Health; Fort Collins, CO, USA: 2001.
  7. Fraile A.P., González-Cubero E., Martínez-Flórez S., Olivera E.R., Villar-Suárez V.. Regenerative Medicine Applied to Musculoskeletal Diseases in Equines: A Systematic Review.. Veter. Sci. 2023;10:666.
    doi: 10.3390/vetsci10120666pmc: PMC10748126pubmed: 38133217google scholar: lookup
  8. O’brien C., Marr N., Thorpe C.. Microdamage in the equine superficial digital flexor tendon.. Equine Veter. J. 2021;53:417–430.
    doi: 10.1111/evj.13331pubmed: 32772396google scholar: lookup
  9. Hosaka Y., Kirisawa R., Yamamoto E., Ueda H., Iwai H., Takehana K.. Localization of cytokines in tendinocytes of the superficial digital flexor tendon in the horse.. J. Veter. Med. Sci. 2002;64:945–947.
    doi: 10.1292/jvms.64.945pubmed: 12419874google scholar: lookup
  10. Reis I.L., Lopes B., Sousa P., Sousa A.C., Caseiro A.R., Mendonça C.M., Santos J.M., Atayde L.M., Alvites R.D., Maurício A.C.. Equine Musculoskeletal Pathologies: Clinical Approaches and Therapeutical Perspectives—A Review.. Veter. Sci. 2024;11:190.
    doi: 10.3390/vetsci11050190pmc: PMC11126110pubmed: 38787162google scholar: lookup
  11. Sharma P., Maffulli N.. Tendon injury and tendinopathy: Healing and repair.. J. Bone Jt. Surg. Am. 2005;87:187–202.
    pubmed: 15634833
  12. M’cloud W.R.C., Guzmán K.E., Panek C.L., Colbath A.C.. Stem cells and platelet-rich plasma for the treatment of naturally occurring equine tendon and ligament injuries: A systematic review and meta-analysis.. J. Am. Veter. Med. Assoc. 2024;262:S50–S60.
    doi: 10.2460/javma.23.12.0723pubmed: 38471305google scholar: lookup
  13. Peng C., Yang L., Labens R., Gao Y., Zhu Y., Li J.. A systematic review and meta-analysis of the efficacy of platelet-rich plasma products for treatment of equine joint disease.. Equine Veter. J. 2024;56:858–869.
    doi: 10.1111/evj.14042pubmed: 38185481google scholar: lookup
  14. Garbin L.C., Lopez C., Carmona J.U.. A Critical Overview of the Use of Platelet-Rich Plasma in Equine Medicine Over the Last Decade.. Front. Veter. Sci. 2021;8:641818.
    doi: 10.3389/fvets.2021.641818pmc: PMC8044532pubmed: 33869321google scholar: lookup
  15. Castillo-Franz C., López C., Carmona J.. Evaluation of the Catabolic and Anabolic Gene Expression Effects and Histology Changes induced by Platelet-Rich Gel Supernatants in Equine Suspensory Ligament Explants Challenged with Lipopolysaccharide.. MLTJ-Muscle Ligaments Tendons J. 2021;11:1–14.
    doi: 10.32098/mltj.01.2021.01google scholar: lookup
  16. Castillo-Franz C., López C., Álvarez M.E., Giraldo C.E., Carmona J.U.. Anti-inflammatory effects of two platelet-rich gel supernatants in an in vitro system of ligament desmitis.. Muscles Ligaments Tendons J. (MLTJ) 2019;9:506–516.
    doi: 10.32098/mltj.04.2019.04google scholar: lookup
  17. Waselau M., Sutter W.W., Genovese R.L., Bertone A.L.. Intralesional injection of platelet-rich plasma followed by controlled exercise for treatment of midbody suspensory ligament desmitis in Standardbred racehorses.. J. Am. Veter. Med. Assoc. 2008;232:1515–1520.
    doi: 10.2460/javma.232.10.1515pubmed: 18479242google scholar: lookup
  18. Argüelles D., Carmona J.U., Climent F., Muñoz E., Prades M.. Autologous platelet concentrates as a treatment for musculoskeletal lesions in five horses.. Veter. Rec. 2008;162:208–211.
    doi: 10.1136/vr.162.7.208pubmed: 18281627google scholar: lookup
  19. Marx R.E.. Platelet-rich plasma (PRP): What is PRP and what is not PRP?. Implant Dent. 2001;10:225–228.
    doi: 10.1097/00008505-200110000-00002pubmed: 11813662google scholar: lookup
  20. Dohan Ehrenfest D.M., Andia I., Zumstein M.A., Zhang C.-Q., Pinto N.R., Bielecki T.. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: Current consensus, clinical implications and perspectives.. Muscles Ligaments Tendons J. 2014;4:3–9.
    doi: 10.32098/mltj.01.2014.02pmc: PMC4049647pubmed: 24932440google scholar: lookup
  21. Dohan Ehrenfest D.M., Rasmusson L., Albrektsson T.. Classification of platelet concentrates: From pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27:158–167.
    doi: 10.1016/j.tibtech.2008.11.009pubmed: 19187989google scholar: lookup
  22. Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E.. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.. BMJ. 2021;372:n71.
    doi: 10.1136/bmj.n71pmc: PMC8005924pubmed: 33782057google scholar: lookup
  23. Page M.J., Moher D., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E.. PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews.. BMJ. 2021;372:n160.
    doi: 10.1136/bmj.n160pmc: PMC8005925pubmed: 33781993google scholar: lookup
  24. Moher D., Shamseer L., Clarke M., Ghersi D., Liberati A., Petticrew M., Shekelle P., Stewart L.A., PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.. Syst. Rev. 2015;4:1–9.
    doi: 10.1186/2046-4053-4-1pmc: PMC4320440pubmed: 25554246google scholar: lookup
  25. Santos C.M.d.C., Pimenta C.A.d.M., Nobre M.R.C.. The PICO strategy for the research question construction and evidence search.. Rev. Latino-Am. Enferm. 2007;15:508–511.
    doi: 10.1590/S0104-11692007000300023pubmed: 17653438google scholar: lookup
  26. Eriksen M.B., Frandsen T.F.. The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: A systematic review.. J. Med. Libr. Assoc. 2018;106:420–431.
    doi: 10.5195/jmla.2018.345pmc: PMC6148624pubmed: 30271283google scholar: lookup
  27. Cooke A., Smith D., Booth A.. Beyond PICO: The SPIDER tool for qualitative evidence synthesis.. Qual. Health Res. 2012;22:1435–1443.
    doi: 10.1177/1049732312452938pubmed: 22829486google scholar: lookup
  28. Harrison P., Alsousou J.. Studies on platelet rich plasma—New editorial policy for “Platelets”.. Platelets. 2020;31:281–282.
    doi: 10.1080/09537104.2020.1729013pubmed: 32124684google scholar: lookup
  29. Sterne J.A.C., Hernán M.A., Reeves B.C., Savović J., Berkman N.D., Viswanathan M., Henry D., Altman D.G., Ansari M.T., Boutron I.. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions.. BMJ. 2016;355:i4919.
    doi: 10.1136/bmj.i4919pmc: PMC5062054pubmed: 27733354google scholar: lookup
  30. Sterne J.A.C., Savović J., Page M.J., Elbers R.G., Blencowe N.S., Boutron I., Cates C.J., Cheng H.Y., Corbett M.S., Eldridge S.M.. RoB 2: A revised tool for assessing risk of bias in randomised trials.. BMJ. 2019;366:l4898.
    doi: 10.1136/bmj.l4898pubmed: 31462531google scholar: lookup
  31. McGuinness L.A., Higgins J.P.T.. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments.. Res. Synth. Methods. 2021;12:55–61.
    doi: 10.1002/jrsm.1411pubmed: 32336025google scholar: lookup
  32. Romagnoli N., Rinnovati R., Ricciardi G., Lambertini C., Spinella G., Spadari A.. Clinical Evaluation of Intralesional Injection of Platelet-Rich Plasma for the Treatment of Proximal Suspensory Ligament Desmitis in Horses.. J. Equine Veter. Sci. 2015;35:141–146.
    doi: 10.1016/j.jevs.2014.12.011google scholar: lookup
  33. Scala M., Lenarduzzi S., Spagnolo F., Trapasso M., Ottonello C., Muraglia A., Barla A., Squillario M., Strada P.. Regenerative Medicine for the Treatment of Teno-desmic Injuries of the Equine. A Series of 150 Horses Treated with Platelet-derived Growth Factors.. In Vivo. 2014;28:1119–1123.
    pubmed: 25398809
  34. Künneke A., Jaugstetter H., Heyers P.. Bone marrow—Autologous conditioned plasma (BM-ACP) in equine medicine—First clinical experience of a new, autologous therapy in the treatment of tendon diseases in horses.. Pferdeheilkunde. 2008;24:519–523.
    doi: 10.21836/PEM20080403google scholar: lookup
  35. Witte S., Dedman C., Harriss F., Kelly G., Chang Y.-M., Witte T.. Comparison of treatment outcomes for superficial digital flexor tendonitis in National Hunt racehorses.. Veter. J. 2016;216:157–163.
    doi: 10.1016/j.tvjl.2016.08.003pubmed: 27687944google scholar: lookup
  36. Marycz K., Toker N.Y., Grzesiak J., Wrzeszcz K., Golonka P.. The therapeutic effect of autogenic adipose derived stem cells combined with autogenic platelet rich plasma in tendons disorders hi horses in vitro and in vivo research.. J. Anim. Vet. Adv. 2012;11:4324–4331.
  37. Castelijns G., Crawford A., Schaffer J., Ortolano G.A., Beauregard T., Smith R.K.W.. Evaluation of a filter-prepared platelet concentrate for the treatment of suspensory branch injuries in horses.. Veter. Comp. Orthop. Traumatol. 2011;24:363–369.
    doi: 10.3415/VCOT-11-01-0001pubmed: 21887455google scholar: lookup
  38. Georg R., Maria C., Gisela A., Bianca C.. Autologous conditioned plasma as therapy of tendon and ligament lesions in seven horses.. J. Veter. Sci. 2010;11:173–175.
    doi: 10.4142/jvs.2010.11.2.173pmc: PMC2873820pubmed: 20458161google scholar: lookup
  39. Zuffova K., Krisova S., Zert Z.. Platelet rich plasma treatment of superficial digital flexor tendon lesions in racing Thoroughbreds.. Veter. Med. 2013;58:230–239.
    doi: 10.17221/6761-VETMEDgoogle scholar: lookup
  40. Beerts C., Suls M., Broeckx S.Y., Seys B., Vandenberghe A., Declercq J., Duchateau L., Vidal M.A., Spaas J.H.. Tenogenically Induced Allogeneic Peripheral Blood Mesenchymal Stem Cells in Allogeneic Platelet-Rich Plasma: 2-Year Follow-up after Tendon or Ligament Treatment in Horses.. Front. Veter. Sci. 2017;4:158.
    doi: 10.3389/fvets.2017.00158pmc: PMC5622984pubmed: 29018808google scholar: lookup
  41. Guercio A., Di Marco P., Casella S., Russotto L., Puglisi F., Majolino C., Giudice E., Di Bella S., Purpari G., Cannella V.. Mesenchymal Stem Cells Derived From Subcutaneous Fat and Platelet-Rich Plasma Used in Athletic Horses With Lameness of the Superficial Digital Flexor Tendon.. J. Equine Veter. Sci. 2015;35:19–26.
    doi: 10.1016/j.jevs.2014.10.006google scholar: lookup
  42. Ricco’ S., Renzi S., Del Bue M., Conti V., Merli E., Ramoni R., Lucarelli E., Gnudi G., Ferrari M., Grolli S.. Allogeneic adipose tissue-derived mesenchymal stem cells in combination with platelet rich plasma are safe and effective in the therapy of superficial digital flexor tendonitis in the horse.. Int. J. Immunopathol. Pharmacol. 2013;26:61–68.
    doi: 10.1177/03946320130260S108pubmed: 24046950google scholar: lookup
  43. Torricelli P., Fini M., Filardo G., Tschon M., Pischedda M., Pacorini A., Kon E., Giardino R.. Regenerative medicine for the treatment of musculoskeletal overuse injuries in competition horses.. Int. Orthop. 2011;35:1569–1576.
    doi: 10.1007/s00264-011-1237-3pmc: PMC3174295pubmed: 21394594google scholar: lookup
  44. Garrett K.S., Bramlage L.R., Spike-Pierce D.L., Cohen N.D.. Injection of platelet- and leukocyte-rich plasma at the junction of the proximal sesamoid bone and the suspensory ligament branch for treatment of yearling Thoroughbreds with proximal sesamoid bone inflammation and associated suspensory ligament branch desmitis.. J. Am. Veter. Med. Assoc. 2013;243:120–125.
    doi: 10.2460/javma.243.1.120pubmed: 23786200google scholar: lookup
  45. Geburek F., Gaus M., van Schie H.T.M., Rohn K., Stadler P.M.. Effect of intralesional platelet-rich plasma (PRP) treatment on clinical and ultrasonographic parameters in equine naturally occurring superficial digital flexor tendinopathies—A randomized prospective controlled clinical trial.. BMC Veter. Res. 2016;12:191.
    doi: 10.1186/s12917-016-0826-1pmc: PMC5015224pubmed: 27604193google scholar: lookup
  46. Giunta K., Donnell J.R., Donnell A.D., Frisbie D.D.. Prospective randomized comparison of platelet rich plasma to extracorporeal shockwave therapy for treatment of proximal suspensory pain in western performance horses.. Res. Veter. Sci. 2019;126:38–44.
    doi: 10.1016/j.rvsc.2019.07.020pubmed: 31430578google scholar: lookup
  47. Maleas G., Mageed M.. Effectiveness of Platelet-Rich Plasma and Bone Marrow Aspirate Concentrate as Treatments for Chronic Hindlimb Proximal Suspensory Desmopathy.. Front. Veter. Sci. 2021;8:678453.
    doi: 10.3389/fvets.2021.678453pmc: PMC8253571pubmed: 34222402google scholar: lookup
  48. Bosch G., Moleman M., Barneveld A., van Weeren P.R., van Schie H.T.M.. The effect of platelet-rich plasma on the neovascularization of surgically created equine superficial digital flexor tendon lesions.. Scand. J. Med. Sci. Sports. 2011;21:554–561.
    doi: 10.1111/j.1600-0838.2009.01070.xpubmed: 20459479google scholar: lookup
  49. Bosch G., van Weeren P.R., Barneveld A., van Schie H.T.. Computerised analysis of standardised ultrasonographic images to monitor the repair of surgically created core lesions in equine superficial digital flexor tendons following treatment with intratendinous platelet rich plasma or placebo.. Veter. J. 2009;187:92–98.
    doi: 10.1016/j.tvjl.2009.10.014pubmed: 19932036google scholar: lookup
  50. Bosch G., van Schie H.T.M., de Groot M.W., Cadby J.A., van de Lest C.H.A., Barneveld A., van Weeren P.R.. Effects of platelet-rich plasma on the quality of repair of mechanically induced core lesions in equine superficial digital flexor tendons: A placebo-controlled experimental study.. J. Orthop. Res. 2010;28:211–217.
    doi: 10.1002/jor.20980pubmed: 19714688google scholar: lookup
  51. Figueiredo M.A.F., Alves G.E.S., Michel A.F.R.M., Lima A.E., Wenceslau A.A., Ferreira M.L., Clark R.M.O., Ayres M.C.C.. Effect of platelet rich plasma therapy in the repair of experimental lesions of the suspensory ligament in horses.. Rev. Bras. Med. Vet. 2016;38:85–92.
  52. Maia L., de Souza M.V., Júnior J.I.R., de Oliveira A.C., Alves G.E.S., Benjamin L.d.A., Silva Y.F.R.S., Zandim B.M., Moreira J.D.C.L.. Platelet-Rich Plasma in the Treatment of Induced Tendinopathy in Horses: Histologic Evaluation.. J. Equine Veter. Sci. 2009;29:618–626.
    doi: 10.1016/j.jevs.2009.07.001google scholar: lookup
  53. Maia L., Souza M.V.D., Alves G.E., Júnior J.I., Oliveira A.C.D., Zandim B.M., da Silva Y.F.. Platelet-rich plasma in the treatment of induced tendinitis in equines: Ultrasonographic evaluation.. Pesqui. Vet. Bras. 2009;29:241–245.
    doi: 10.1590/S0100-736X2009000300009google scholar: lookup
  54. Zandim B.M., De Souza M.V., Frassy L.N., Vilória M.I.V., Maia L., Fonseca C.C., Valente F.L., Moreira J.d.C.L., Magalhães P.C.. Immunohistochemistry of factor VIII, histology and morphometry in equine tendon treated with platelet-rich plasma.. Rev. Bras. Med. Vet. 2013;35:169–184.
  55. Carvalho A.d.M., Badial P.R., Álvarez L.E.C., Yamada A.L.M., Borges A.S., Deffune E., Hussni C.A., Alves A.L.G.. Equine tendonitis therapy using mesenchymal stem cells and platelet concentrates: A randomized controlled trial.. Stem Cell Res. Ther. 2013;4:85.
    doi: 10.1186/scrt236pmc: PMC3854756pubmed: 23876512google scholar: lookup
  56. Romero A., Barrachina L., Ranera B., Remacha A., Moreno B., de Blas I., Sanz A., Vázquez F., Vitoria A., Junquera C.. Comparison of autologous bone marrow and adipose tissue derived mesenchymal stem cells, and platelet rich plasma, for treating surgically induced lesions of the equine superficial digital flexor tendon.. Veter. J. 2017;224:76–84.
    doi: 10.1016/j.tvjl.2017.04.005pubmed: 28697880google scholar: lookup
  57. McCarrel T.M., Minas T., Fortier L.A.. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy.. J. Bone Jt. Surg. 2012;94:e143.
    doi: 10.2106/JBJS.L.00019pubmed: 23032594google scholar: lookup
  58. Giraldo C.E., Álvarez M.E., Carmona J.U.. Influence of calcium salts and bovine thrombin on growth factor release from equine platelet-rich gel supernatants.. Veter. Comp. Orthop. Traumatol. 2017;30:1–7.
    doi: 10.3415/VCOT-16-02-0026pubmed: 27849108google scholar: lookup
  59. Textor J.A., Tablin F.. Intra-articular use of a platelet-rich product in normal horses: Clinical signs and cytologic responses.. Veter. Surg. 2013;42:499–510.
    doi: 10.1111/j.1532-950X.2013.12015.xpubmed: 23631631google scholar: lookup
  60. Textor J.A., Tablin F.. Activation of equine platelet-rich plasma: Comparison of methods and characterization of equine autologous thrombin.. Veter. Surg. 2012;41:784–794.
    doi: 10.1111/j.1532-950X.2012.01016.xpubmed: 22742830google scholar: lookup
  61. Tsiapalis D., O’driscoll L.. Mesenchymal Stem Cell Derived Extracellular Vesicles for Tissue Engineering and Regenerative Medicine Applications.. Cells. 2020;9:991.
    doi: 10.3390/cells9040991pmc: PMC7226943pubmed: 32316248google scholar: lookup
  62. Lee J.Y., Kim H.-S.. Extracellular Vesicles in Regenerative Medicine: Potentials and Challenges.. Tissue Eng. Regen. Med. 2021;18:479–484.
    doi: 10.1007/s13770-021-00365-wpmc: PMC8300067pubmed: 34297340google scholar: lookup
  63. Burnouf T., Chou M.-L., Lundy D.J., Chuang E.-Y., Tseng C.-L., Goubran H.. Expanding applications of allogeneic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery.. J. Biomed. Sci. 2023;30:79.
    doi: 10.1186/s12929-023-00972-wpmc: PMC10500824pubmed: 37704991google scholar: lookup
  64. Nazaroff J., Oyadomari S., Brown N., Wang D.. Reporting in clinical studies on platelet-rich plasma therapy among all medical specialties: A systematic review of Level I and II studies.. PLoS ONE. 2021;16:e0250007.
    doi: 10.1371/journal.pone.0250007pmc: PMC8064527pubmed: 33891618google scholar: lookup
  65. Chahla J., Cinque M.E., Piuzzi N.S., Mannava S., Geeslin A.G., Murray I.R., Dornan G.J., Muschler G.F., LaPrade R.F.. A Call for Standardization in Platelet-Rich Plasma Preparation Protocols and Composition Reporting: A Systematic Review of the Clinical Orthopaedic Literature.. J. Bone Jt. Surg. Am. 2017;99:1769–1779.
    doi: 10.2106/JBJS.16.01374pubmed: 29040132google scholar: lookup
  66. Murray I.R., Geeslin A.G., Goudie E.B., Petrigliano F.A., LaPrade R.F.. Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO): Platelet-Rich Plasma and Mesenchymal Stem Cells.. J. Bone Jt. Surg. 2017;99:809–819.
    doi: 10.2106/JBJS.16.00793pubmed: 28509821google scholar: lookup
  67. Paul J., Barari M.. Meta-analysis and traditional systematic literature reviews—What, why, when, where, and how?. Psychol. Mark. 2022;39:1099–1115.
    doi: 10.1002/mar.21657google scholar: lookup
Subscribe to our newsletter
Join 99,359 horse owners like you who receive our email updates on horse health and nutrition.